In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 2066-2069

  Ji, Baohong ^a   Lounis, Nacer ^a   Maslo, Caroline ^a   Truffot Pernot, Chantal ^a   Bonnafous, Pascale ^a   Grosset, Jacques ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; ISONIAZID; MOXIFLOXACIN; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG INJURY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN WEIGHT; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0031879709     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.2066     Document Type: Article

References (27)

1. Aldridge, K. E., and D. Ashcratt. 1997. Comparison of the in vitro activities of BAY 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob. Agents Chemother. 41:709-711.
2. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
3. Bayer Pharma. 1996. Investigator's drug brochure: Bay 12-8039, version 2. Bayer Pharma, Puteaux, France.
4. Bayer Pharma. Unpublished data.
5. Brueggemann, A. B., K. C. Kugler, and G. V. Doern. 1997. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 41:1594-1597.
6. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
7. Ferguson, J., H. Al-Ajmi, R. Kubin, S. Daggett, and P. S. Saggu. 1998. A double-blind, placebo and lomefloxacin controlled human volunteer phototest study to determine the photosensitising potential of oral moxifloxacin (BAY 12-8039), abstr. 59.001. In Program and abstracts of the 8th International Congress on Infectious Diseases. Boston, Mass. 15 to 18 May 1998.
8. Fernandes, C. J., and V. P. Ackerman. 1992. The in vitro activity of CI-960 (clinafloxacin) and CI-990 against routine and multiresistant clinical isolates, p. 10-11. In Proceedings on posters presented at the 4th International Symposium on New Quinolones, Munich, Germany, 27 to 29 August 1992.
9. Godfrey, K. 1985. Statistics in practice. Comparing the means of several groups. N. Engl. J. Med. 313:1450-1456.
10. Goldstein, E. J. C. 1996. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin. Infect. Dis. 23(Suppl. 1):S25-S30.
11. Goldstein, E. J. C., D. M. Citron, M. Hudspeth, S. H. Gerardo, and C. V. Merriam. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob. Agents Chemother. 41:1552-1557.
12. Grosset, J., N. Lounis, C. Truffot-Pernot, R. J. O'Brien, M. C. Raviglione, and B. Ji. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am. J. Respir. Crit. Care Med., in press.
13. Ji, B., C. Truffot-Pernot, and J. Grosset. 1991. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. Tubercle 72: 181-186.
14. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1994. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother. 38:2521-2529.
15. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
16. Ji, B., L. Levy, and J. H. Grosset. 1996. Chemotherapy of leprosy: progress since the Orlando Congress, and prospects for the future. Int. J. Lepr. 64:S80-S90.
17. Lalande V., C. Truffot-Pernot, A. Paccaly-Moulin, J. Grosset and B. Ji. 1993. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 37:407-413.
18. Lounis, N., B. Ji, C. Truffot-Pernot, and J. Grosset. 1997. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob. Agents Chemother. 41:607-610.
19. Petersen, U., S. Bartel, K. D. Bremm, T. Himmler, A. Krebs, and T. Schenke. 1996. The synthesis and biological properties of 6-fluoroquinolone-carboxylic acids. Bull. Soc. Chim. Belg. 105:683-698.
20. Renau, T., J. W. Gage, J. A. Dever, G. E. Roland, E. T. Joannides, M. A. Shapiro, J. P. Sanchez, S. J. Gracheck, J. M. Domagala, M. R. Jacobs, and R. C. Reynolds. 1996. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob. Agents Chemother. 40:2363-2368.
21. Sougakoff, W. Personal communication.
22. Stass, H., A. Dalhoff, D. Kubitza, and U. Schühly. 1998. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone administered to healthy subjects. Antimicrob. Agents Chemother. 42:2060-2065.
23. Stein, G. E. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23(Suppl. 1):S19-S24.
24. Truffot-Pernot, C., B. Ji, and J. Grosset. 1991. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiment. Tubercle 72:57-64.
25. Visalli, M. A., M. R. Jacobs, and P. C. Appelbaum. 1996. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. J. Antimicrob. Chemother. 37:77-84.
26. Vohr, H. W., G. Wasinska-Kempka, and H. J. Ahr. 1996. Studies on the phototoxic potential of a new 8-methoxy-quinolone: BAY 12-8039, abstr. F21, p. 103. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
27. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.